10-Q: Nordicus Partners Q3: R&D Advances Amidst Rising Losses

Nordicus Partners reports increased net losses for the nine months ended December 31, 2025, despite significant R&D progress in its biotech portfolio and a substantial cash infusion from financing activities.

Summary

• Nordicus Partners Corporation reported a net loss of $1,247,524 for the three months ended December 31, 2025, a decrease from $1,545,311 in the prior year period.
• For the nine months ended December 31, 2025, the net loss increased significantly to $3,965,884, compared to $2,310,876 for the same period in 2024.
• The company generated no revenue for both the three and nine months ended December 31, 2025, consistent with its preclinical stage.
• Cash balance increased to $189,297 as of December 31, 2025, from $19,914 as of March 31, 2025, primarily due to financing activities.
• Total assets grew to $75,856,649 as of December 31, 2025, from $70,246,329 as of March 31, 2025.
• Research and development expenses increased by 7% to $445,459 for the three months and by 74% to $1,323,809 for the nine months ended December 31, 2025, reflecting increased activity in acquired subsidiaries.
• General and administrative expenses surged by 157% to $296,088 for the three months and by 224% to $710,227 for the nine months ended December 31, 2025, driven by increased travel, investor relations, and D&O insurance costs.
• The company raised $3.9 million in net proceeds from the issuance of 1,687,536 restricted common shares to private investors during the nine months ended December 31, 2025.
• Nordicus Partners formed a new subsidiary, NoviThera Aps, in October 2025, focused on developing a novel Monoclonal antibody for psoriasis, acquiring 50.1% ownership.
• Orocidin A/S, a subsidiary, successfully completed a 14-day toxicology study in hamsters and a Beagle Dog Study, showing high drug tolerance and direct effect on periodontitis.
• Bio-Convert A/S, another subsidiary, received positive scientific advice from the Danish Medicines Agency (DKMA) for its lead candidate, QR-02, for oral leukoplakia, potentially paving the way for a First in Human trial without prior animal studies.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While the company shows promising preclinical R&D progress and has successfully raised capital, the significant increase in nine-month net losses and operating cash burn, coupled with the explicit 'going concern' doubt and ineffective internal controls, indicates substantial financial challenges and high risk.

Positives

• Cash balance significantly increased to $189,297 as of December 31, 2025, from $19,914 as of March 31, 2025, providing improved short-term liquidity.
• Net loss for the three months ended December 31, 2025, decreased to $1,247,524 from $1,545,311 in the comparable prior year period.
• Orocidin A/S successfully completed a 14-day toxicology study in hamsters, demonstrating high drug tolerance with no adverse reactions or tissue changes, providing a foundation for an upcoming 8-week toxicity study.
• Orocidin A/S's Beagle Dog Study showed QR-01 having a direct effect on periodontitis, with consistent improvements across key clinical endpoints and good tolerability, strengthening confidence for human pilot efficacy studies.
• Bio-Convert A/S received positive and constructive scientific advice from the Danish Medicines Agency (DKMA) for its lead candidate, QR-02, for oral leukoplakia, indicating a high likelihood of animal studies being dispensable for the proposed First in Human trial.
• The formation of NoviThera Aps in October 2025 diversifies the company's preclinical biotechnology portfolio into psoriasis treatment.
• The company successfully raised $3.9 million through private placements of common stock during the nine months ended December 31, 2025.

Negatives

• The company reported a substantial increase in net loss for the nine months ended December 31, 2025, reaching $3,965,884, up from $2,310,876 in the prior year period.
• Operating cash flow showed a significant increase in cash used, totaling $3,649,699 for the nine months ended December 31, 2025, compared to $899,517 in the prior year, indicating a higher cash burn rate.
• The accumulated deficit grew to $50,730,422 as of December 31, 2025, highlighting continued unprofitability since inception.
• Disclosure controls and procedures were deemed not effective as of December 31, 2025, due to limited resources in finance and accounting functions.
• General and administrative expenses increased significantly by 224% for the nine months ended December 31, 2025, impacting overall profitability.
• The company has recognized nominal revenue and continues to operate in a pre-revenue phase, relying heavily on financing activities.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, as current funds are insufficient to meet needs for more than twelve months.
• The ability to generate profitable operations in the future is uncertain and dependent on obtaining necessary financing.
• The success of the company's products relies on the results of research and development, clinical testing, and trial activities, which are inherently uncertain.
• Obtaining regulatory approval to market products is a critical and uncertain factor for future success.
• Competition from products manufactured, sold, or being developed by other companies poses a significant risk.
• The company's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products is crucial.
• Fluctuations in foreign currency exchange rates can impact financial results, particularly given the Danish Krone-denominated assets of its subsidiaries.
• The company's internal control over financial reporting may be adversely affected by significant deficiencies and material weaknesses due to limited resources in finance and accounting functions.

Future Outlook

Nordicus Partners intends to finance operating costs over the next twelve months with existing cash and through private placements of Common Stock. The company has applied to uplist its common stock to the Nasdaq Capital Market, aiming to raise capital through the sale of its common stock on terms available to Nasdaq-listed entities. Orocidin is preparing for an upcoming pivotal 8-week toxicity study and a human pilot efficacy study. Bio-Convert is moving towards a First in Human trial for QR-02. NoviThera's key focus is to develop a human rat model to test its novel Monoclonal antibody for psoriasis in relevant animal disease models.

Management Comments

• Management intends to finance operating costs over the next twelve months with existing cash on hand and through private placements of Common Stock.
• The company's mission is to back high-growth ventures and transformative innovations in the life sciences sector, providing capital, strategic guidance, and operational resources.
• Nordicus's portfolio diversification strategy aims to position it as a stable and resilient company, mitigating risk with significant upside potential.
• The company's approach blends strategic counsel, operational know-how, and the cultivation of meaningful partnerships to strengthen market positions and achieve growth ambitions.

Industry Context

StockSavvy.ai notes that Nordicus Partners operates as a business accelerator and holding company within the Nordic life sciences sector, aiming to bridge Nordic innovation with U.S. operational expertise. Its current portfolio consists of three preclinical biotechnology companies (Orocidin, Bio-Convert, NoviThera) focused on oral health and psoriasis, targeting high-growth markets with unmet medical needs. This model positions Nordicus as an early-stage investor and developer in specialized biotech niches, seeking to scale and exit high-potential ventures.

Comparison to Industry Standards

• As a preclinical-stage biotechnology holding company, Nordicus Partners' financial performance (zero revenue, significant R&D expenses, and net losses) is typical for companies in the early phases of drug development, where substantial investment is required before commercialization.
• The successful completion of toxicology and efficacy studies by Orocidin and positive scientific advice for Bio-Convert's QR-02 are critical milestones that, if continued, could align with the progress seen in successful preclinical biotech firms like early-stage Moderna (mRNA-1273 development) or BioNTech (BNT162b2 development) before their clinical breakthroughs, though Nordicus's scale and therapeutic areas differ.
• The company's accumulated deficit of over $50 million is common for biotech firms that have not yet brought a product to market, similar to many small-cap biotechs that rely on continuous capital raises to fund extensive R&D pipelines.
• The increase in G&A and professional fees, while impacting losses, is often observed in growing holding companies expanding their operational footprint and preparing for potential uplisting, akin to companies like BridgeBio Pharma in its early growth phases, which also manages a diverse portfolio of early-stage assets.

Management Changes

Corporate Governance

Related Party Transactions

• GK Partners ApS (related party) was involved in the acquisition of equity interests in Mag Mile Capital, Inc. on June 20, 2023.
• GK Partners ApS purchased 49,000 shares of the company's common stock for $245,000 during the nine months ended December 31, 2025.
• Bennett Yankowitz, the company's chief financial officer and director, is affiliated with legal counsel (the Affiliate) who provided general legal services, resulting in legal fees of $9,813 for the three months and $26,305 for the nine months ended December 31, 2025.
• Henrik Rouf, CEO, had his annual salary increased to $360,000, effective July 1, 2025.
• Bennett Yankowitz, CFO and Director, had his annual salary increased to $120,000, effective July 1, 2025.
• The Darlington Group, LLC, controlled by Andrew Ritter (a member of the company's board of directors), entered into a consulting agreement on October 1, 2025, for $10,000 per quarter for strategic guidance and operational support.
• In October 2025, the company's subsidiary NoviThera purchased intellectual property from Alteral Therapeutics (a related party controlled by Allan Wehnert, CEO of NoviThera) in exchange for a 49.9% equity stake in NoviThera.

Stakeholder Impact

• Shareholders: Experience dilution from ongoing private placements of common stock but also benefit from potential value creation through R&D milestones and strategic acquisitions. The share repurchase program could offer some support to existing shareholders.
• Employees: Key executives received significant salary increases, indicating management's commitment to retaining talent. The expansion of the board and new subsidiary formation may create new opportunities.
• Customers (future patients): Stand to benefit from the development of novel therapies for periodontitis, oral leukoplakia, and psoriasis, addressing unmet medical needs.
• Creditors: The 'going concern' doubt raises concerns about the company's ability to meet its obligations in the long term, although recent capital raises provide short-term liquidity.
• Suppliers: Increased R&D and G&A expenses suggest higher engagement with service providers and vendors.

Next Steps

• Orocidin A/S will proceed with a pivotal 8-week toxicity study.
• Orocidin A/S is preparing for an upcoming human pilot efficacy study.
• Bio-Convert A/S is moving towards a First in Human trial for its lead candidate, QR-02.
• NoviThera Aps plans to develop a human rat model to test its novel Monoclonal antibody for psoriasis in other relevant animal disease models.
• The company intends to continue financing operating costs through existing cash and private placements.
• Nordicus Partners will continue efforts to uplist its common stock to the Nasdaq Capital Market to facilitate future capital raises.
• Management intends to take appropriate and reasonable steps to make improvements to remediate deficiencies in disclosure controls and procedures.

Key Dates

Recommendation

The company faces significant financial challenges, including substantial net losses and a 'going concern' warning, which typically warrants a 'sell' or 'strong sell'. However, the strategic acquisitions, promising preclinical R&D progress in multiple therapeutic areas (Orocidin, Bio-Convert, NoviThera), and successful capital raises provide a glimmer of long-term potential. The planned Nasdaq uplisting could also unlock further financing opportunities. Given the high risk but also the potential for future value creation if R&D milestones are met, a 'hold' recommendation is appropriate for investors with a high-risk tolerance who are willing to monitor the company's progress closely, rather than a 'sell' which would disregard the R&D upside, or a 'buy' which would overlook the severe financial risks.

Keywords

Biotechnology, Life Sciences, Oral Health, Periodontitis, Oral Leukoplakia, Psoriasis, Preclinical Development, R&D, SEC Filing, 10-Q, Nordicus Partners, Biomaterials, Drug Development